Alexion Pharmaceuticals, Inc.: Shareholders Board Members Managers and Company Profile | US0153511094

Business description: Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company's marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.

Number of employees: 3,837

Sales by Activity: Alexion Pharmaceuticals, Inc.

Fiscal Period: December	2019 (USD)	2020 (USD)
Biotechnology	4.99B	6.07B

See all business segments

Geographical breakdown of sales: Alexion Pharmaceuticals, Inc.

Fiscal Period: December	2019 (USD)	2020 (USD)
United States	2.76B	3.6B
Europe	1.21B	1.33B
Asia Pacific	528M	664M
Rest of World	493M	475M

See all geographic segments

Executive Committee: Alexion Pharmaceuticals, Inc.

Manager	Title	Age	Since
Marc Dunoyer CEO	Chief Executive Officer	73	-
Sean Christie DFI	Director of Finance/CFO	53	2021-07-31
Doyle Shane COO	Chief Operating Officer	-	-
Christophe Hotermans CTO	Chief Tech/Sci/R&D Officer	-	2021-06-30
Ruth Diazaraque CTO	Chief Tech/Sci/R&D Officer	-	2023-05-31

See ALEXION PHARMACEUTICALS, INC. governance

Composition of the Board of Directors: Alexion Pharmaceuticals, Inc.

Director	Title	Age	Since
Ruud Dobber BRD	Director/Board Member	-	-

Composition of the Board of Directors

Company details: Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard

02210, Boston

+(475) 230-2596

http://www.alexion.com

address Alexion Pharmaceuticals, Inc.(ALXN)

Group companies: Alexion Pharmaceuticals, Inc.

Name	Category and Sector
Alexion Business Services Pvt Ltd. Alexion Business Services Pvt Ltd. Data Processing ServicesTechnology Services Provides data processing and preparation services	Data Processing Services
Alexion Pharma International Operations Ltd. Alexion Pharma International Operations Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products	Pharmaceuticals: Major
Alexion Pharma Holding Unlimited Co. Alexion Pharma Holding Unlimited Co. Pharmaceuticals: MajorHealth Technology Develops biologic therapeutic products	Pharmaceuticals: Major
Alexion Pharma GmbH Alexion Pharma GmbH BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders	Biotechnology

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.99%	+0.97%	+53.80%	+108.02%	1,043B
JOHNSON & JOHNSON	-0.87%	-0.14%	+51.15%	+66.54%	649B
ABBVIE INC.	-0.51%	+0.54%	+18.57%	+70.67%	469B
ROCHE HOLDING AG	-0.25%	+0.19%	+36.95%	+45.54%	355B
NOVARTIS AG	+0.98%	+2.91%	+20.59%	+27.14%	270B
ASTRAZENECA PLC	-1.91%	+2.42%	+10.41%	+11.04%	262B
AMGEN INC.	-1.22%	+7.83%	+41.49%	+52.07%	222B
GILEAD SCIENCES, INC.	-1.54%	+1.97%	+31.64%	+101.25%	189B
NOVO NORDISK A/S	-2.53%	-7.47%	-32.63%	-60.41%	175B
Average	-0.99%	+2.20%	+25.77%	+46.87%	403.67B
Weighted average by Cap.	-1.06%	+2.19%	+35.47%	+64.81%